An increase in high-fat, high-fructose foods in people's diets has contributed to a dramatic increase in type 2 diabetes.

If you’re suffering from stabbing pain, numbness, tingling or a burning sensation in your arms, legs, hands or feet, you may ...

Oxford Cannabinoid Technologies is shedding its old skin. Having delisted its stock last year, the biotech is rebranding as ...

Introduction Neuropathic pain is a persistent pain condition caused by nerve damage or dysfunction in the nervous system. It is distinct from n ...

Octavian Therapeutics ("Octavian" or "the Company"), a leading clinical-stage innovator in neuropathic pain treatment, today announces a transformative rebrand, the appointment of a new Non-Executive ...

Results also show that reducing the Padcev dose at treatment initiation may benefit older patients with urothelial carcinoma, ...

Healthcare isn't the hottest sector these days. While the S&P 500 has soared nearly 21% over the last 12 months, healthcare ...

Completion of SON-1010 (IL12-FHAB) monotherapy dose escalation in Phase 1 SB101 trial; Stable disease (SD) at four months post-initiation of ...

Administered as a once-weekly subcutaneous injection, Ozempic not only helps control blood glucose levels but also reduces ...

Just over a year after its first phase 3 trial of its Engensis gene therapy for painful diabetic peripheral neuropathy (DPN) bombed, Helixmith has started dosing patients in a new study.

Patients with BRAF V600E-mutated metastatic colorectal cancer experienced improved responses when treated with Braftovi plus Erbitux and mFOLFOX6.

Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application ...